Skip to main content
James Goydos, MD, General Surgery, Philadelphia, PA

JamesSGoydosMD

General Surgery Philadelphia, PA

Surgical Oncology (Other than Breast)

American Association for Cancer Research (AACR); Clinical Cancer Research Journal

Dr. Goydos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Goydos' full profile

Already have an account?

Summary

  • Dr. James S. Goydos is a general surgeon in New Brunswick, New Jersey and is affiliated with multiple hospitals in the area. He has been in practice for more than 20 years.

Clinical Expertise

  • Skin cancer, Melanoma, Soft tissue cancer, Soft tissue sarcomas, Oncology, Surgical oncology (non-breast), Merkel cell carcinoma, Skin cancer surgery, Health education, Biochemistry

Education & Training

  • University of Connecticut
    University of ConnecticutResidency, Surgery, 1988 - 1993
  • Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical SchoolClass of 1988

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1995 - 2021

Awards, Honors, & Recognition

  • ACS Fellow
  • Inside Jersey Top Doctors for Cancer Castle Connolly, 2012-2014
  • Inside Jersey Magazine Top Doctors Castle Connolly, 2010-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Melanoma & Skin Cancer Patient & Caregiver Symposium 
    Cancer Institute Of New Jersey Cinj - 5/16/2017
  • Treatment of Locally and Regionally Advanced Melanoma 
    Rutgers Cancer Institute of New Jersey - 9/13/2014

Other

Authored Content

  • Can You Get a Sunburn in the Winter?December 2021
  • Can You Get a Sunburn in the Winter?December 2021
  • When Do Americans Get Their Freedom BackNovember 2021
  • Melanoma Knows No SeasonNovember 2021
  • The Importance of Breast Cancer AwarenessOctober 2021
  • Rates of Skin Cancer in New Jersey Higher Than the National AverageSeptember 2021
  • How Both The Mentor And The Mentee Help Each Other SucceedAugust 2021
  • Humans Are Never Far From Chaos And BarbarismAugust 2021
  • Everyday Ways to Give Back to the CommunityJuly 2021
  • Any Competent Public Health Doctor Could Predict What Would Happen During The PandemicMay 2021
  • Any Competent Public Health Doctor Could Predict What Would Happen During The PandemicMay 2021
  • How a Trauma Death Can Turn Doctors into Better SurgeonsMay 2021
  • How a Trauma Death Can Turn Doctors into Better SurgeonsMay 2021
  • What Ever Happened to the Concept of the Absent-Minded Professor?April 2021
  • What Ever Happened to the Concept of the Absent-Minded Professor?April 2021
  • The Trolley Problem & The Pandemic: What Would You Choose?January 2021
  • What You May Not Know About Breast CancerOctober 2020
  • Coronavirus and Physician Burnout Are Adding Fuel to the FireOctober 2020
  • Why ‘White Coat Syndrome’ and The Pandemic Are A Double ThreatOctober 2020
  • Why Do We Still Use Fax Machines In Medicine?October 2020
  • Join now to see all

Press Mentions

  • On Memorial Day, We Should Talk Skin Cancer in the Military
    On Memorial Day, We Should Talk Skin Cancer in the MilitaryMay 28th, 2022
  • When Do Americans Get Their Freedom Back?
    When Do Americans Get Their Freedom Back?September 14th, 2021
  • Biohaven Announces First Patient Treated in Clinical Research Collaboration At Rutgers Cancer Institute
    Biohaven Announces First Patient Treated in Clinical Research Collaboration At Rutgers Cancer InstituteMay 18th, 2020
  • Join now to see all

Grant Support

  • Regulation of tumor released exosomes and glutamatergic signalingNational Cancer Institute2014–2017
  • Combination Therapy that Targets Glutamate Signaling in MelanomaNational Cancer Institute2010–2015
  • A Patient Oriented Research Program for Surgical OncologistsNational Cancer Institute2010–2015
  • Validation of Grm1 as a Therapeutic Target in MelanomaNational Cancer Institute2007–2013
  • A Phase II Trial of Riluzole in Patients with Advanced MelanomaNational Cancer Institute2009–2011
  • A Phase 0 Trial of Riluzole in Patients with Resectable Stage III or IV MelanomaNational Cancer Institute2007–2008

Professional Memberships

Other Languages

  • Spanish